Delivering on Growth Engines
As it enters a new phase of acceleration, Teva continues to advance innovative medicines across key therapeutic areas, with a strong focus on neuroscience, supporting patients who deal with some of the world’s most challenging and under- treated conditions. As part of its Pivot to Growth strategy, Teva has accelerated its innovative portfolio to $2.3 billion, representing 30% growth over the last two years, with the potential for $4 billion in innovative sales by 2027. At a recent strategy day presentation to industry professionals, Eric Hughes, Executive VP Global R&D and Chief Medical Officer, outlined the future vision.
Key takeaways:
- Teva has accelerated its innovative portfolio to $2.3 billion, representing 30% growth over the last two years.
- Teva’s focus includes neuroscience and growing immunology expertise.
- Priority conditions highlighted here include schizophrenia, tardive dyskinesia (TD), Huntington’s disease (HD), and migraine.
Executive perspective
“Our focus on neuroscience is building on a heritage we’ve had at Teva for decades now and also building on our burgeoning immunology expertise.”
Eric Hughes, Executive VP Global R&D and Chief Medical Officer
Conditions we are focused on
With a portfolio that includes treatments for conditions such as schizophrenia, tardive dyskinesia (TD), Huntington’s disease (HD) and migraine, we’re working to deliver solutions for patients with complex, long-term conditions, driving progress in areas of high unmet need.
“Accelerating our growth engines is all about delivering for our patients,” says Chris Fox, Executive VP Teva Commercial US. “We’ve added $1 billion in revenue to our innovative portfolio between 2022 and 2025. And we continue to accelerate.”
How we are delivering for patients
Schizophrenia
Mental health is a top priority at Teva because we recognize the immense impact that conditions like schizophrenia and bipolar disorder have on patients and their communities. Read more
People living with schizophrenia often have limited awareness of their illness and because of that, taking oral medication, potentially for the rest of their lives, is a challenge. Subsequently, adherence rates for all schizophrenia treatments are poor.
Mark Suett, Senior Director Teva Medical Affairs
Find out how Teva is working to answer this challenge
Tardive dyskinesia (TD)
TD is a serious disorder, which can arise as a side effect of prolonged use of certain medications, and is characterized by repetitive, uncontrollable body movements. As well as providing treatments, we believe education is key to supporting patients with TD.
“Driving awareness is one of our biggest priorities, as we recognize that many patients do not recognize they have TD. This gap in knowledge creates a ripple effect, instigating a lack of diagnosis and lack of treatment. People don’t know that this can be addressed.”
Chris Fox, Executive VP Teva Commercial US
Discover how patients can advocate for themselves and how loved ones can support someone living with the condition
What you should know about Tardive dyskinesia
Huntington’s disease (HD)
HD is a rare, inherited condition that leads to the progressive breakdown of nerve cells in the brain, impacting physical movements, cognitive abilities and emotional stability.
It’s a cruel diagnosis, but I won’t let it crush my spirit. I will view Huntington’s disease as a prism from which painful distortion comes with a colorful range of emotions.
Sarah Foster, HD patient
Caring for a patient with Huntington’s disease: read Heather’s story
Find out more about Huntington’s disease
Migraine
A severe, debilitating condition, migraine is estimated to affect more than 10% of people worldwide. Through innovative therapies and a deep understanding of neurological conditions, Teva aims to provide solutions addressing both the pain and the long-term challenges.
Personal perspective
I recommend having a regular regime, taking care of yourself and your mental well-being. Also, having pre-prepared meals in the freezer so you don't have to cook can be very helpful.
Hana Chalupníková, Commercial Support Specialist, Teva Prague
Teva has helped to pioneer the development of the Migraine Friendly Workplace Stamp initiative with the European Headache & Migraine Alliance (EMHA). Find out more
What you should know about migraine
NPS-ALL-NP-01710 FEBRUARY 2026
Teva’s Pivot to Growth strategy has reshaped the company’s future. Now it’s time to accelerate. Find out more
- Did you know that one third of the world lives with a neurological condition, making it one of the leading causes of illness and disability worldwide? Find out more
- How we can all help destigmatize and actively change the discussion around schizophrenia
- Discover 5 ways to find hope with Huntington’s disease
- Interested in getting involved in the work that we do? Explore a career at Teva
